Comment by
Actuarial on Mar 25, 2021 1:42pm
Only one member voted yes and he/she is one of the two consumer reps. What a failure! "Outside experts advising the FDA voted 19 to 1 against (one of the two consumer reps voted yes) Pfizer’s potential osteoarthritis drug tanezumab, saying the proposed risk evaluation and mitigation strategy (REMS) will not ensure the benefits of the drug outweigh the risks."
Comment by
YukonJezza on Mar 25, 2021 1:47pm
would be smart for Pfizer to scraptanezumab. The should BuY ATE out .
Comment by
Straylight on Mar 25, 2021 1:58pm
Reading that article I was thinking the same thing.
Comment by
markymark11 on Mar 25, 2021 2:39pm
It would be nice if Dan released a statement on the back of this FDA/Tanezumab news to reiterate Otenaproxesul's potential as a best-in-class NSAID for OA pain.
Comment by
Marky1 on Mar 25, 2021 3:00pm
MarkyMark....why don't you write him and tell him your thoughts! Dan is great on answering letters...I forwarded that article to him...if he responds I shall put It on here...We need some catalyst to get our SP to a value that is realistic...been a long long voyage, but our day will be coming very soon...There I are just too many positives available. ...Come on Dan...I believe!
Comment by
Notthatbright on Mar 25, 2021 3:14pm
Dan is goverened by the BOD. He alone cannot represent himself or the Company. We, as much as we hate to wait, must wait. IMO
Comment by
endpntplay on Mar 25, 2021 3:16pm
I think the best way forward is to include the FDAs own comments on an expensive drug like this in their own FDA filings to support approval for Otena.